KIT and non-small cell lung carcinoma: Examples include imatinib for gastrointestinal stromal tumors with mutant c-KIT kinase or chronic myelogenous leukemia with BCR-ABL gene translocations, erlotinib for non-small-cell lung cancer (NSCLC) with mutant epidermal growth factor receptor (EGFR), and sunitinib targeting the von Hippel–Lindau tumor suppressor (VHL)-dependent vascular endothelial growth factor (VEGF) pathway in renal cell carcinoma [106,107,108].